NITAZOXANIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2002)
Entry Type: Small molecule
Molecule Category: UNKNOWN Prodrug
ATC: P01AX11
UNII: SOA12P041N

Structure
InChI Key YQNQNVDNTFHQSW-UHFFFAOYSA-N
Smile CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1
InChI
InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)

Physicochemical Descriptors

Property Name Value
Molecular Formula C12H9N3O5S
Molecular Weight 307.29
AlogP 2.23
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 111.43
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 21.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Pyruvate:ferredoxin oxidoreductase inhibitor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Oxidoreductase
- 8220 - 10500 -
Enzyme Transferase
- 9700 - - 11-100.65
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- 1011 - - 98.28-109.78
Ion channel Other ion channel Chloride channel Calcium-activated chloride channel
- 424 - - -
Transcription factor
- 9800-9980 - - 54.6
Unclassified protein
- - 85400 - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Amebiasis 4 D000562 ClinicalTrials
Diarrhea 4 D003967 FDA
Brain Diseases 3 D001927 ClinicalTrials
Cryptosporidiosis 3 D003457 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Peritonitis 3 D010538 ClinicalTrials
Respiratory Tract Diseases 3 D012140 ClinicalTrials
Clostridium Infections 3 D003015 ClinicalTrials
Helicobacter Infections 3 D016481 ClinicalTrials
Enterocolitis, Pseudomembranous 3 D004761 ClinicalTrials
Arthritis, Rheumatoid 3 D001172 ClinicalTrials
Dyspepsia 3 D004415 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Influenza, Human 3 D007251 ClinicalTrials
Diabetes Mellitus, Type 2 2 D003924 ClinicalTrials
Hepatitis C 2 D006526 ClinicalTrials
Bronchiolitis 2 D001988 ClinicalTrials
Gastroenteritis 2 D005759 ClinicalTrials
Hepatitis C, Chronic 2 D019698 ClinicalTrials
Hepatitis B, Chronic 2 D019694 ClinicalTrials
Malnutrition 2 D044342 ClinicalTrials
Periodontitis 2 D010518 ClinicalTrials
Tuberculosis 2 D014376 ClinicalTrials
Sexually Transmitted Diseases 2 D012749 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Irritable Bowel Syndrome 1 D043183 ClinicalTrials
HIV Infections 1 D015658 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
31.28
General disorders and administration site conditions
10.5
Renal and urinary disorders
10.5
Nervous system disorders
8.22
Skin and subcutaneous tissue disorders
6.85
Cardiac disorders
4.11
Immune system disorders
3.88
Respiratory, thoracic and mediastinal disorders
3.65
Vascular disorders
3.42
Musculoskeletal and connective tissue disorders
2.97
Eye disorders
2.51
Psychiatric disorders
2.28

Cross References

Resources Reference
CAS NUMBER 55981-09-4
ChEBI 94807
ChEMBL CHEMBL1401
DrugBank DB00507
DrugCentral 1943
EPA CompTox DTXSID5033757
FDA SRS SOA12P041N
Human Metabolome Database HMDB14649
PDB NTI
PharmGKB PA164754874
PubChem 41684
SureChEMBL SCHEMBL40981
ZINC ZINC000003956788
CONTENTS